CD8A and cholangiocarcinoma: Moreover, the combination of anti-CD40/PD-1 therapy led to an increased number of CD4+ and CD8+ T cells, CAF cells and myeloid cells in the tumor, which were shown to drive immunotherapy resistance in CCA [94].